. Author manuscript; available in PMC: 2014 Jul 31.

Published in final edited form as: Biol Blood Marrow Transplant. 2012 Oct 27;19(1 0):S102–S108. doi: 10.1016/j.bbmt.2012.10.028

Table 2.

Comparison of Recipients of Ex Vivo T Cell Transplants at Memorial Sloan Kettering Cancer Center and T Cell—Replete Transplants at M.D. Anderson Cancer Center

	MSKCC; Ex Vivo T Cell Depletion (n = 115), %(95%CI)	M.D. Anderson; T Cell Replete (Tacrolimus/MTX) (n = 181), %(95%CI)	HR (95% CI)	P Value
Acute GVHD II-IV at day 100	5(2–11)	18 (13–24)	3.9 (1.5–9.9)	.005
Chronic GVHD at 3 years	13 (8–22)	53 (46–62)	4.6(2.6–8.1)	<.001
NRM
Day 100	8 (4–15)	3 (1–7)	0.4(0.1–1.1)	.07
3 year	24(17–34)	16(11–23)	0.6(0.3–1.1)	.10
PFS at 3 years	18 (12–27)	25 (19–33)	1.3 (0.8–2.3)	.30
OS at 3 years	57 (47–67)	66 (58–74)	0.7(0.5–1.1)	.20